| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Q Fever | 10 | 2023 | 38 | 4.600 |
Why?
|
| Coxiella burnetii | 9 | 2023 | 37 | 4.030 |
Why?
|
| Chemokine CXCL12 | 19 | 2023 | 457 | 3.770 |
Why?
|
| Islets of Langerhans Transplantation | 9 | 2024 | 748 | 2.550 |
Why?
|
| Bacterial Vaccines | 7 | 2022 | 400 | 2.120 |
Why?
|
| Receptors, CXCR4 | 9 | 2021 | 729 | 1.790 |
Why?
|
| Heterocyclic Compounds | 5 | 2019 | 245 | 1.740 |
Why?
|
| B-Lymphocytes | 10 | 2024 | 4785 | 1.420 |
Why?
|
| Alginates | 4 | 2023 | 250 | 1.380 |
Why?
|
| Chemotaxis, Leukocyte | 9 | 2010 | 660 | 1.360 |
Why?
|
| HSP70 Heat-Shock Proteins | 3 | 2018 | 395 | 1.270 |
Why?
|
| HIV Envelope Protein gp120 | 7 | 2011 | 925 | 1.250 |
Why?
|
| Vaccines | 5 | 2018 | 842 | 1.200 |
Why?
|
| Adjuvants, Immunologic | 5 | 2018 | 998 | 1.080 |
Why?
|
| Islets of Langerhans | 2 | 2023 | 1350 | 1.050 |
Why?
|
| Insulin-Secreting Cells | 4 | 2024 | 899 | 0.980 |
Why?
|
| Skin | 8 | 2021 | 4499 | 0.970 |
Why?
|
| GPI-Linked Proteins | 2 | 2018 | 473 | 0.930 |
Why?
|
| T-Lymphocytes | 17 | 2022 | 10267 | 0.920 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2020 | 1122 | 0.890 |
Why?
|
| Lasers | 3 | 2018 | 952 | 0.890 |
Why?
|
| Epitopes, T-Lymphocyte | 4 | 2022 | 827 | 0.820 |
Why?
|
| Thymus Gland | 6 | 2007 | 1266 | 0.800 |
Why?
|
| Influenza Vaccines | 5 | 2017 | 780 | 0.740 |
Why?
|
| Immunomodulation | 4 | 2024 | 549 | 0.710 |
Why?
|
| Avidin | 2 | 2024 | 44 | 0.690 |
Why?
|
| Mesothelioma | 2 | 2018 | 811 | 0.670 |
Why?
|
| Benzylamines | 6 | 2020 | 251 | 0.660 |
Why?
|
| Cancer Vaccines | 3 | 2018 | 1042 | 0.650 |
Why?
|
| Drug Discovery | 3 | 2017 | 1067 | 0.640 |
Why?
|
| Ovarian Neoplasms | 4 | 2019 | 4907 | 0.620 |
Why?
|
| Wound Healing | 2 | 2021 | 2813 | 0.620 |
Why?
|
| Chemokines, CXC | 7 | 2007 | 420 | 0.610 |
Why?
|
| Immunity, Cellular | 3 | 2020 | 1561 | 0.610 |
Why?
|
| CD4-Positive T-Lymphocytes | 10 | 2019 | 4411 | 0.600 |
Why?
|
| Animals | 68 | 2024 | 169337 | 0.600 |
Why?
|
| Acquired Immunodeficiency Syndrome | 7 | 2008 | 2202 | 0.600 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2024 | 3440 | 0.590 |
Why?
|
| Tumor Microenvironment | 7 | 2024 | 3939 | 0.580 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2021 | 582 | 0.570 |
Why?
|
| Dendritic Cells | 8 | 2018 | 2749 | 0.570 |
Why?
|
| Infrared Rays | 3 | 2018 | 249 | 0.570 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 3 | 2011 | 545 | 0.570 |
Why?
|
| Mice, Inbred C57BL | 21 | 2024 | 22355 | 0.560 |
Why?
|
| Vaccination | 8 | 2022 | 3431 | 0.560 |
Why?
|
| HIV-1 | 15 | 2010 | 6963 | 0.550 |
Why?
|
| Simian immunodeficiency virus | 3 | 2011 | 814 | 0.530 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 426 | 0.520 |
Why?
|
| Antigens, Bacterial | 2 | 2019 | 1150 | 0.520 |
Why?
|
| Mice | 38 | 2024 | 82017 | 0.500 |
Why?
|
| Injections, Intradermal | 4 | 2018 | 116 | 0.490 |
Why?
|
| Guinea Pigs | 3 | 2022 | 1309 | 0.450 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2014 | 148 | 0.450 |
Why?
|
| Chemotaxis | 5 | 2011 | 600 | 0.450 |
Why?
|
| Regeneration | 2 | 2021 | 1525 | 0.450 |
Why?
|
| Graft Survival | 4 | 2023 | 3900 | 0.440 |
Why?
|
| Viral Vaccines | 2 | 2022 | 596 | 0.440 |
Why?
|
| Lymphopoiesis | 2 | 2005 | 133 | 0.440 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2024 | 1473 | 0.430 |
Why?
|
| Antigens, CD34 | 6 | 2001 | 656 | 0.420 |
Why?
|
| Lassa Fever | 1 | 2014 | 97 | 0.420 |
Why?
|
| Immunity, Innate | 4 | 2023 | 3078 | 0.410 |
Why?
|
| Interleukin-8 | 2 | 2005 | 705 | 0.410 |
Why?
|
| Flow Cytometry | 6 | 2017 | 5900 | 0.400 |
Why?
|
| Immunologic Memory | 1 | 2019 | 1374 | 0.390 |
Why?
|
| Wounds and Injuries | 2 | 2021 | 2514 | 0.380 |
Why?
|
| Antibodies, Viral | 5 | 2024 | 3211 | 0.380 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2014 | 450 | 0.380 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2013 | 255 | 0.370 |
Why?
|
| Immunocompetence | 1 | 2011 | 138 | 0.370 |
Why?
|
| Antibodies, Bacterial | 3 | 2022 | 1478 | 0.360 |
Why?
|
| Cytokines | 4 | 2023 | 7445 | 0.360 |
Why?
|
| Immune Tolerance | 2 | 2019 | 2324 | 0.360 |
Why?
|
| Stem Cells | 3 | 2021 | 3539 | 0.350 |
Why?
|
| Immunity, Humoral | 3 | 2024 | 611 | 0.350 |
Why?
|
| Spleen | 3 | 2009 | 2296 | 0.350 |
Why?
|
| Influenza A virus | 1 | 2013 | 460 | 0.340 |
Why?
|
| Primates | 2 | 2023 | 521 | 0.340 |
Why?
|
| Paclitaxel | 1 | 2017 | 1736 | 0.340 |
Why?
|
| Brain Injuries | 1 | 2021 | 2059 | 0.340 |
Why?
|
| Biological Assay | 2 | 2010 | 627 | 0.330 |
Why?
|
| Antibodies, Neutralizing | 4 | 2024 | 2006 | 0.320 |
Why?
|
| Skin Diseases | 1 | 2017 | 1084 | 0.320 |
Why?
|
| Immunotherapy | 5 | 2024 | 4738 | 0.320 |
Why?
|
| Gene Products, tat | 2 | 1999 | 111 | 0.310 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2017 | 1105 | 0.310 |
Why?
|
| Lymph Nodes | 2 | 2011 | 3471 | 0.310 |
Why?
|
| HIV Antigens | 1 | 2009 | 328 | 0.310 |
Why?
|
| Mice, Transgenic | 5 | 2024 | 9562 | 0.300 |
Why?
|
| Signal Transduction | 11 | 2021 | 23631 | 0.300 |
Why?
|
| Disease Models, Animal | 8 | 2024 | 18362 | 0.290 |
Why?
|
| Organoids | 2 | 2007 | 746 | 0.290 |
Why?
|
| Humans | 97 | 2024 | 768393 | 0.280 |
Why?
|
| Neutrophils | 4 | 2015 | 3785 | 0.280 |
Why?
|
| Interferon-gamma | 4 | 2021 | 3164 | 0.280 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 3610 | 0.270 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2024 | 3731 | 0.270 |
Why?
|
| Immunophenotyping | 5 | 2021 | 1866 | 0.270 |
Why?
|
| Cell Migration Inhibition | 1 | 2006 | 97 | 0.260 |
Why?
|
| Monocytes | 5 | 2020 | 2595 | 0.260 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2011 | 3112 | 0.260 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2005 | 58 | 0.260 |
Why?
|
| Drug Approval | 1 | 2012 | 818 | 0.240 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2001 | 664 | 0.240 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 5891 | 0.240 |
Why?
|
| Viral Envelope Proteins | 1 | 2008 | 641 | 0.240 |
Why?
|
| HIV Infections | 13 | 2020 | 17575 | 0.230 |
Why?
|
| Hematopoietic Stem Cells | 6 | 2005 | 3407 | 0.230 |
Why?
|
| Ovalbumin | 3 | 2014 | 677 | 0.230 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2020 | 3813 | 0.230 |
Why?
|
| Seroepidemiologic Studies | 2 | 2022 | 405 | 0.230 |
Why?
|
| Pilot Projects | 3 | 2023 | 8731 | 0.230 |
Why?
|
| Colorimetry | 1 | 2024 | 151 | 0.220 |
Why?
|
| Zoonoses | 2 | 2021 | 180 | 0.220 |
Why?
|
| Transplantation, Heterologous | 3 | 2023 | 2394 | 0.220 |
Why?
|
| Immune System | 2 | 2008 | 801 | 0.220 |
Why?
|
| Neoplasms | 8 | 2024 | 22385 | 0.220 |
Why?
|
| Drug Synergism | 2 | 2018 | 1762 | 0.220 |
Why?
|
| Biotin | 1 | 2024 | 256 | 0.220 |
Why?
|
| Immunization | 3 | 2019 | 1219 | 0.210 |
Why?
|
| Melanoma, Experimental | 1 | 2006 | 559 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2022 | 4646 | 0.200 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 2060 | 0.200 |
Why?
|
| Mice, Inbred BALB C | 3 | 2020 | 6234 | 0.200 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3118 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3241 | 0.200 |
Why?
|
| Cricetulus | 2 | 2018 | 813 | 0.200 |
Why?
|
| Forkhead Transcription Factors | 1 | 2009 | 1623 | 0.200 |
Why?
|
| Enzyme-Linked Immunospot Assay | 2 | 2019 | 126 | 0.200 |
Why?
|
| Antibody Formation | 2 | 2021 | 1393 | 0.200 |
Why?
|
| Tissue Array Analysis | 2 | 2017 | 551 | 0.190 |
Why?
|
| Female | 35 | 2024 | 397089 | 0.190 |
Why?
|
| Capsules | 2 | 2021 | 193 | 0.190 |
Why?
|
| Chemotactic Factors | 2 | 2015 | 197 | 0.190 |
Why?
|
| Cell Line, Tumor | 7 | 2019 | 17135 | 0.190 |
Why?
|
| Australia | 2 | 2022 | 1265 | 0.190 |
Why?
|
| CHO Cells | 2 | 2018 | 1380 | 0.190 |
Why?
|
| Epitopes | 2 | 2022 | 2525 | 0.180 |
Why?
|
| Virus Replication | 3 | 1999 | 2458 | 0.180 |
Why?
|
| Models, Immunological | 1 | 2003 | 518 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 11854 | 0.180 |
Why?
|
| Bacterial Proteins | 1 | 2014 | 3838 | 0.180 |
Why?
|
| Cricetinae | 2 | 2018 | 2423 | 0.170 |
Why?
|
| Cell Movement | 5 | 2018 | 5215 | 0.170 |
Why?
|
| Societies, Scientific | 1 | 2021 | 223 | 0.170 |
Why?
|
| Pertussis Toxin | 3 | 2005 | 176 | 0.170 |
Why?
|
| Leukocytes | 1 | 2008 | 2030 | 0.170 |
Why?
|
| Membrane Glycoproteins | 2 | 2008 | 3712 | 0.170 |
Why?
|
| Interleukin-10 | 2 | 2023 | 1184 | 0.170 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2024 | 798 | 0.170 |
Why?
|
| Asparagine | 2 | 1989 | 120 | 0.170 |
Why?
|
| HIV Seroprevalence | 2 | 1996 | 89 | 0.160 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1999 | 98 | 0.160 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2005 | 823 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2023 | 4357 | 0.160 |
Why?
|
| Artificial Organs | 1 | 2000 | 149 | 0.160 |
Why?
|
| Chondrosarcoma | 1 | 2021 | 306 | 0.160 |
Why?
|
| HLA-DR Antigens | 1 | 2020 | 607 | 0.160 |
Why?
|
| Antigens, CD | 3 | 2011 | 4031 | 0.150 |
Why?
|
| Receptors, CXCR | 1 | 2018 | 52 | 0.150 |
Why?
|
| Toll-Like Receptors | 1 | 2021 | 582 | 0.150 |
Why?
|
| Complement C3 | 2 | 1989 | 434 | 0.150 |
Why?
|
| Papillomavirus Infections | 1 | 2009 | 1640 | 0.140 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2009 | 2044 | 0.140 |
Why?
|
| Mucous Membrane | 2 | 2011 | 659 | 0.140 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2017 | 23 | 0.140 |
Why?
|
| Aspartic Acid | 2 | 1989 | 577 | 0.140 |
Why?
|
| Lasers, Semiconductor | 1 | 2017 | 43 | 0.140 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2018 | 1795 | 0.140 |
Why?
|
| Injections, Subcutaneous | 1 | 2018 | 687 | 0.140 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 2 | 2015 | 221 | 0.140 |
Why?
|
| Cell Growth Processes | 1 | 2017 | 381 | 0.140 |
Why?
|
| Swine | 3 | 2023 | 5994 | 0.140 |
Why?
|
| Administration, Intranasal | 1 | 2018 | 485 | 0.140 |
Why?
|
| Tissue Engineering | 1 | 2007 | 1891 | 0.130 |
Why?
|
| Insulin | 3 | 2021 | 6607 | 0.130 |
Why?
|
| Receptors, CCR5 | 2 | 2011 | 491 | 0.130 |
Why?
|
| Neuroprotective Agents | 1 | 2023 | 957 | 0.130 |
Why?
|
| Macaca mulatta | 4 | 2011 | 2362 | 0.130 |
Why?
|
| Hospital Units | 1 | 1997 | 142 | 0.130 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1997 | 242 | 0.130 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 890 | 0.130 |
Why?
|
| Genomic Instability | 1 | 2020 | 715 | 0.130 |
Why?
|
| Cells, Cultured | 8 | 2018 | 19022 | 0.120 |
Why?
|
| Peptides | 3 | 2022 | 4353 | 0.120 |
Why?
|
| Hexuronic Acids | 1 | 2015 | 145 | 0.120 |
Why?
|
| Glucuronic Acid | 1 | 2015 | 150 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2017 | 10776 | 0.120 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1995 | 79 | 0.120 |
Why?
|
| Antibody Specificity | 2 | 2020 | 1065 | 0.120 |
Why?
|
| Cell Proliferation | 6 | 2018 | 10478 | 0.120 |
Why?
|
| Coculture Techniques | 4 | 2009 | 1342 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2017 | 720 | 0.120 |
Why?
|
| HLA-DR3 Antigen | 1 | 2014 | 24 | 0.110 |
Why?
|
| Anti-HIV Agents | 5 | 2020 | 4571 | 0.110 |
Why?
|
| Aspergillus fumigatus | 1 | 2015 | 158 | 0.110 |
Why?
|
| Ferritins | 1 | 2017 | 600 | 0.110 |
Why?
|
| Sequence Analysis, RNA | 2 | 2022 | 2038 | 0.110 |
Why?
|
| Systems Biology | 1 | 2017 | 479 | 0.110 |
Why?
|
| Cell Death | 2 | 2011 | 1682 | 0.110 |
Why?
|
| Methylprednisolone | 2 | 1985 | 387 | 0.110 |
Why?
|
| AIDS Vaccines | 2 | 2010 | 900 | 0.110 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 4365 | 0.110 |
Why?
|
| HLA Antigens | 1 | 2019 | 1337 | 0.110 |
Why?
|
| HIV Antibodies | 2 | 1998 | 1341 | 0.110 |
Why?
|
| HIV-2 | 1 | 1994 | 156 | 0.110 |
Why?
|
| Hypersensitivity | 1 | 2022 | 1173 | 0.110 |
Why?
|
| Lassa virus | 1 | 2014 | 99 | 0.110 |
Why?
|
| Russia | 1 | 2014 | 386 | 0.110 |
Why?
|
| Hematopoiesis | 2 | 2005 | 2058 | 0.100 |
Why?
|
| Antigens | 1 | 2018 | 1443 | 0.100 |
Why?
|
| London | 4 | 1997 | 233 | 0.100 |
Why?
|
| Fetus | 4 | 2005 | 1883 | 0.100 |
Why?
|
| Mast Cells | 2 | 2018 | 1407 | 0.100 |
Why?
|
| Antigen Presentation | 2 | 2009 | 1251 | 0.100 |
Why?
|
| Inflammation | 4 | 2010 | 10863 | 0.100 |
Why?
|
| Genetic Vectors | 4 | 1998 | 3413 | 0.100 |
Why?
|
| Male | 22 | 2024 | 364902 | 0.100 |
Why?
|
| Chronic Disease | 4 | 2019 | 9379 | 0.100 |
Why?
|
| Mouth Neoplasms | 1 | 2017 | 597 | 0.100 |
Why?
|
| HIV Seropositivity | 2 | 1995 | 962 | 0.100 |
Why?
|
| Osteosarcoma | 1 | 2018 | 911 | 0.100 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2000 | 1813 | 0.100 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 1238 | 0.100 |
Why?
|
| Interleukin-1 | 1 | 2015 | 1251 | 0.100 |
Why?
|
| Laser Therapy | 1 | 2018 | 1105 | 0.090 |
Why?
|
| Microscopy, Confocal | 1 | 2017 | 1974 | 0.090 |
Why?
|
| DNA, Viral | 3 | 1999 | 2205 | 0.090 |
Why?
|
| Gene Products, gag | 2 | 2011 | 317 | 0.090 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 2206 | 0.090 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 937 | 0.090 |
Why?
|
| Defective Viruses | 1 | 1991 | 89 | 0.090 |
Why?
|
| Mice, Knockout | 3 | 2021 | 14481 | 0.090 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1997 | 846 | 0.090 |
Why?
|
| Genes, env | 1 | 2010 | 95 | 0.090 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 13576 | 0.090 |
Why?
|
| Protein Engineering | 1 | 2014 | 549 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 2 | 2009 | 2709 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2021 | 1855 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 1602 | 0.080 |
Why?
|
| Peritoneal Cavity | 1 | 2010 | 135 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2012 | 550 | 0.080 |
Why?
|
| Fluorescent Dyes | 1 | 2017 | 1926 | 0.080 |
Why?
|
| Cholesterol Ester Storage Disease | 1 | 1989 | 2 | 0.080 |
Why?
|
| Antibodies | 1 | 2017 | 2425 | 0.080 |
Why?
|
| Vaccines, Synthetic | 2 | 2022 | 622 | 0.080 |
Why?
|
| Sterol Esterase | 1 | 1989 | 39 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 3 | 2023 | 2003 | 0.080 |
Why?
|
| Mesentery | 1 | 2010 | 202 | 0.080 |
Why?
|
| Chemokine CCL5 | 1 | 2009 | 214 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 5336 | 0.080 |
Why?
|
| Cell Division | 5 | 1999 | 4479 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2021 | 2336 | 0.080 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 1989 | 99 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 1943 | 0.080 |
Why?
|
| Interleukin-6 | 3 | 2023 | 3230 | 0.080 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 2 | 1999 | 120 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2019 | 2990 | 0.080 |
Why?
|
| Cell Survival | 2 | 2017 | 5792 | 0.080 |
Why?
|
| Survival Rate | 4 | 2011 | 12870 | 0.080 |
Why?
|
| Cell Communication | 2 | 2008 | 1660 | 0.080 |
Why?
|
| Middle Aged | 13 | 2024 | 223491 | 0.080 |
Why?
|
| Emergency Service, Hospital | 3 | 1997 | 7955 | 0.070 |
Why?
|
| Chickens | 1 | 2010 | 845 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 2708 | 0.070 |
Why?
|
| Adoptive Transfer | 1 | 2010 | 824 | 0.070 |
Why?
|
| Lymphoid Tissue | 1 | 2008 | 446 | 0.070 |
Why?
|
| Molecular Sequence Data | 5 | 2010 | 17626 | 0.070 |
Why?
|
| Heart | 1 | 2020 | 4449 | 0.070 |
Why?
|
| Acute Disease | 1 | 2017 | 7242 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 1608 | 0.070 |
Why?
|
| Receptors, Calcium-Sensing | 2 | 2005 | 318 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2014 | 6510 | 0.070 |
Why?
|
| Liver | 2 | 2005 | 7574 | 0.070 |
Why?
|
| Vaginal Smears | 1 | 2009 | 505 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 4 | 2010 | 6085 | 0.070 |
Why?
|
| Alkaline Phosphatase | 1 | 2009 | 864 | 0.070 |
Why?
|
| Peroxidase | 1 | 2009 | 609 | 0.070 |
Why?
|
| Self Tolerance | 1 | 2007 | 123 | 0.070 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 4834 | 0.070 |
Why?
|
| Interleukin-2 | 2 | 2023 | 1894 | 0.060 |
Why?
|
| Single-Cell Analysis | 1 | 2017 | 2533 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 8562 | 0.060 |
Why?
|
| Apoptosis | 3 | 2011 | 9516 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 1 | 2009 | 962 | 0.060 |
Why?
|
| Cell Line | 5 | 2007 | 15597 | 0.060 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2006 | 359 | 0.060 |
Why?
|
| Phenotype | 3 | 2021 | 16721 | 0.060 |
Why?
|
| Biopsy | 1 | 2017 | 6808 | 0.060 |
Why?
|
| In Situ Hybridization | 1 | 2009 | 1905 | 0.060 |
Why?
|
| Cell Separation | 3 | 2001 | 1726 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2006 | 2568 | 0.060 |
Why?
|
| Pseudopodia | 1 | 2005 | 167 | 0.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2012 | 1903 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 21162 | 0.060 |
Why?
|
| Myocardium | 2 | 2009 | 4788 | 0.060 |
Why?
|
| Endothelium, Vascular | 2 | 2009 | 4427 | 0.060 |
Why?
|
| Transgenes | 2 | 1999 | 1015 | 0.060 |
Why?
|
| Cell Culture Techniques | 3 | 2004 | 1667 | 0.060 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 3827 | 0.060 |
Why?
|
| Time Factors | 6 | 2011 | 40272 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2019 | 6430 | 0.060 |
Why?
|
| Adult | 15 | 2022 | 223640 | 0.060 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2005 | 279 | 0.060 |
Why?
|
| Myocardial Contraction | 1 | 2009 | 1527 | 0.060 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2004 | 317 | 0.060 |
Why?
|
| Proviruses | 2 | 1999 | 320 | 0.060 |
Why?
|
| Equipment Design | 2 | 2017 | 3529 | 0.060 |
Why?
|
| Rats | 3 | 2010 | 23835 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2011 | 1248 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 6856 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2009 | 1140 | 0.050 |
Why?
|
| Cytoskeleton | 2 | 2005 | 1176 | 0.050 |
Why?
|
| Organ Culture Techniques | 1 | 2005 | 796 | 0.050 |
Why?
|
| Histamine | 2 | 2004 | 499 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 10377 | 0.050 |
Why?
|
| Isoantibodies | 1 | 2007 | 682 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2007 | 1524 | 0.050 |
Why?
|
| Transfection | 1 | 1991 | 5764 | 0.050 |
Why?
|
| Genetic Engineering | 2 | 2007 | 936 | 0.050 |
Why?
|
| Mutation | 3 | 2024 | 30228 | 0.050 |
Why?
|
| Gene Transfer Techniques | 2 | 1998 | 1209 | 0.050 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2014 | 1929 | 0.050 |
Why?
|
| RNA Interference | 1 | 2011 | 2836 | 0.050 |
Why?
|
| Macrophages | 1 | 2017 | 5796 | 0.050 |
Why?
|
| Cell Polarity | 1 | 2005 | 640 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 5192 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2009 | 1410 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2006 | 1355 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2014 | 10117 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2009 | 5037 | 0.050 |
Why?
|
| Base Sequence | 4 | 1999 | 12422 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 4069 | 0.050 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2001 | 38 | 0.050 |
Why?
|
| Clinical Competence | 2 | 2001 | 4848 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2014 | 3695 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2005 | 1468 | 0.050 |
Why?
|
| Immunoglobulin G | 3 | 2022 | 4570 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 9510 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2008 | 3102 | 0.050 |
Why?
|
| NAD+ Nucleosidase | 1 | 2001 | 43 | 0.050 |
Why?
|
| Enzymes | 1 | 1983 | 254 | 0.050 |
Why?
|
| Immune Evasion | 1 | 2024 | 376 | 0.050 |
Why?
|
| Protein Kinase C | 1 | 2005 | 1207 | 0.050 |
Why?
|
| Integrins | 1 | 2005 | 843 | 0.050 |
Why?
|
| Chemokine CXCL10 | 1 | 2022 | 312 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 11120 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2009 | 13423 | 0.050 |
Why?
|
| Gene Expression | 2 | 2019 | 7598 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 13697 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2018 | 65379 | 0.040 |
Why?
|
| Catalysis | 1 | 2022 | 768 | 0.040 |
Why?
|
| Diffusion Chambers, Culture | 1 | 2000 | 49 | 0.040 |
Why?
|
| Organ Specificity | 2 | 2005 | 1967 | 0.040 |
Why?
|
| Asparaginase | 1 | 1982 | 240 | 0.040 |
Why?
|
| Virulence Factors, Bordetella | 1 | 2000 | 154 | 0.040 |
Why?
|
| Cell Differentiation | 5 | 2018 | 11668 | 0.040 |
Why?
|
| Warts | 1 | 2020 | 66 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2000 | 946 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2022 | 793 | 0.040 |
Why?
|
| Receptors, CCR2 | 2 | 2017 | 216 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 330 | 0.040 |
Why?
|
| Bone Marrow Cells | 3 | 2006 | 2414 | 0.040 |
Why?
|
| Axons | 1 | 2008 | 1678 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8753 | 0.040 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2002 | 305 | 0.040 |
Why?
|
| Liposomes | 1 | 2004 | 792 | 0.040 |
Why?
|
| United States | 2 | 2021 | 73150 | 0.040 |
Why?
|
| Culture Techniques | 1 | 2000 | 530 | 0.040 |
Why?
|
| Disease Progression | 3 | 2010 | 13646 | 0.040 |
Why?
|
| Graft Rejection | 2 | 2020 | 4505 | 0.040 |
Why?
|
| Convalescence | 1 | 2019 | 109 | 0.040 |
Why?
|
| Stroke | 1 | 2021 | 9742 | 0.040 |
Why?
|
| Leukocyte Count | 3 | 1991 | 1605 | 0.040 |
Why?
|
| Drug Contamination | 1 | 2020 | 151 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 640 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 1989 | 4250 | 0.040 |
Why?
|
| Thalidomide | 1 | 2024 | 886 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2009 | 8199 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2023 | 832 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 2001 | 921 | 0.040 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2000 | 311 | 0.040 |
Why?
|
| CD40 Ligand | 1 | 2020 | 524 | 0.040 |
Why?
|
| Leukemia Virus, Murine | 1 | 1998 | 95 | 0.040 |
Why?
|
| Histocompatibility Testing | 1 | 2019 | 716 | 0.040 |
Why?
|
| Cell Transformation, Viral | 1 | 1999 | 530 | 0.040 |
Why?
|
| Injury Severity Score | 1 | 2021 | 1046 | 0.040 |
Why?
|
| Pancreas Transplantation | 1 | 2018 | 198 | 0.040 |
Why?
|
| Mannose-Binding Lectins | 1 | 2017 | 99 | 0.030 |
Why?
|
| Immunoassay | 1 | 2020 | 745 | 0.030 |
Why?
|
| Clonal Anergy | 1 | 2017 | 169 | 0.030 |
Why?
|
| Adolescent | 4 | 2018 | 89184 | 0.030 |
Why?
|
| Young Adult | 3 | 2018 | 60049 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2009 | 5151 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 1999 | 432 | 0.030 |
Why?
|
| Carbon | 1 | 2000 | 672 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 1999 | 902 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2009 | 3941 | 0.030 |
Why?
|
| Zebrafish | 1 | 2008 | 3037 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2002 | 1337 | 0.030 |
Why?
|
| Cell Lineage | 2 | 2009 | 2574 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 2884 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2021 | 1703 | 0.030 |
Why?
|
| Membranes, Artificial | 2 | 1976 | 367 | 0.030 |
Why?
|
| Asthma | 2 | 1985 | 6280 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2006 | 1508 | 0.030 |
Why?
|
| Binding Sites | 1 | 2024 | 6017 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 1528 | 0.030 |
Why?
|
| Cats | 1 | 1997 | 978 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2006 | 2139 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 1997 | 500 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 1839 | 0.030 |
Why?
|
| Retroviridae | 1 | 1998 | 849 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2019 | 1438 | 0.030 |
Why?
|
| DNA Primers | 1 | 1999 | 2825 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2005 | 2589 | 0.030 |
Why?
|
| Retrospective Studies | 7 | 2022 | 81801 | 0.030 |
Why?
|
| Cell Count | 1 | 1999 | 1833 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2017 | 848 | 0.030 |
Why?
|
| Phosphatidylcholines | 1 | 1976 | 406 | 0.030 |
Why?
|
| Microglia | 1 | 2023 | 1374 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 591 | 0.030 |
Why?
|
| AIDS Serodiagnosis | 1 | 1995 | 220 | 0.030 |
Why?
|
| Transients and Migrants | 1 | 1996 | 170 | 0.030 |
Why?
|
| Patient Admission | 1 | 2001 | 1367 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2018 | 731 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 810 | 0.030 |
Why?
|
| Truth Disclosure | 1 | 1997 | 433 | 0.030 |
Why?
|
| ROC Curve | 1 | 2021 | 3623 | 0.030 |
Why?
|
| Bacterial Infections | 1 | 2001 | 1397 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2017 | 1616 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 1362 | 0.030 |
Why?
|
| Arthralgia | 1 | 2017 | 459 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2000 | 2204 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 4588 | 0.030 |
Why?
|
| Protein Binding | 1 | 2024 | 9343 | 0.020 |
Why?
|
| Exanthema | 1 | 2017 | 503 | 0.020 |
Why?
|
| Prednisone | 1 | 2017 | 1567 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2003 | 5496 | 0.020 |
Why?
|
| Models, Biological | 1 | 2008 | 9493 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 2544 | 0.020 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2017 | 542 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2021 | 4291 | 0.020 |
Why?
|
| Pluripotent Stem Cells | 1 | 2018 | 808 | 0.020 |
Why?
|
| Pancreas | 1 | 2018 | 1702 | 0.020 |
Why?
|
| AIDS-Related Complex | 1 | 1991 | 107 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2020 | 6350 | 0.020 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2015 | 446 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2000 | 2819 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 2146 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2017 | 1070 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2017 | 2636 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1991 | 777 | 0.020 |
Why?
|
| Hospitals, General | 1 | 1995 | 807 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2000 | 2929 | 0.020 |
Why?
|
| HIV | 1 | 1997 | 1596 | 0.020 |
Why?
|
| Viral Proteins | 1 | 1997 | 1802 | 0.020 |
Why?
|
| Albumins | 2 | 1983 | 577 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2021 | 3579 | 0.020 |
Why?
|
| Boston | 2 | 2018 | 9371 | 0.020 |
Why?
|
| Fever | 1 | 2017 | 1620 | 0.020 |
Why?
|
| Drug Resistance | 2 | 1985 | 1595 | 0.020 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 1989 | 112 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 1356 | 0.020 |
Why?
|
| Aged | 4 | 2019 | 171562 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 11516 | 0.020 |
Why?
|
| Urban Population | 1 | 1996 | 2045 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2018 | 2389 | 0.020 |
Why?
|
| Critical Illness | 1 | 2021 | 2755 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 8051 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 2257 | 0.020 |
Why?
|
| Catalase | 1 | 1968 | 215 | 0.020 |
Why?
|
| Deficiency Diseases | 1 | 1968 | 74 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 1991 | 564 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3801 | 0.020 |
Why?
|
| Codon | 1 | 1989 | 599 | 0.020 |
Why?
|
| Massachusetts | 1 | 2020 | 8902 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2022 | 12805 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2010 | 437 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2017 | 2168 | 0.020 |
Why?
|
| Length of Stay | 1 | 2021 | 6519 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 1989 | 386 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 12092 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1989 | 1731 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 1682 | 0.020 |
Why?
|
| Hospitals | 1 | 2020 | 3906 | 0.020 |
Why?
|
| Creatine Kinase, BB Form | 1 | 2006 | 7 | 0.020 |
Why?
|
| Calcium | 1 | 2000 | 5794 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6541 | 0.020 |
Why?
|
| Cholesterol | 1 | 1976 | 2912 | 0.020 |
Why?
|
| Histamine Release | 1 | 1986 | 134 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 1989 | 491 | 0.020 |
Why?
|
| Caseins | 1 | 2006 | 105 | 0.020 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2006 | 202 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2009 | 725 | 0.020 |
Why?
|
| Plasmids | 1 | 1991 | 2268 | 0.020 |
Why?
|
| Hybrid Cells | 1 | 1985 | 421 | 0.020 |
Why?
|
| Rectum | 1 | 2010 | 902 | 0.020 |
Why?
|
| Polymers | 2 | 1983 | 1630 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 14737 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1986 | 355 | 0.020 |
Why?
|
| Receptor, Insulin | 1 | 1989 | 838 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 1991 | 1748 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1984 | 351 | 0.010 |
Why?
|
| Vagina | 1 | 2010 | 845 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 1997 | 3627 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 1982 | 5443 | 0.010 |
Why?
|
| Aging | 1 | 2003 | 8764 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2010 | 2596 | 0.010 |
Why?
|
| Prednisolone | 1 | 1984 | 327 | 0.010 |
Why?
|
| Enzyme Therapy | 1 | 1983 | 8 | 0.010 |
Why?
|
| Lymphokines | 1 | 1986 | 927 | 0.010 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2006 | 511 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2021 | 22296 | 0.010 |
Why?
|
| Lysosomes | 1 | 1989 | 939 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2010 | 1794 | 0.010 |
Why?
|
| Physicians | 1 | 2001 | 4614 | 0.010 |
Why?
|
| Synovial Membrane | 1 | 1986 | 536 | 0.010 |
Why?
|
| Chemistry, Physical | 1 | 1983 | 153 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1991 | 2611 | 0.010 |
Why?
|
| Chemical Phenomena | 1 | 1983 | 486 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 1998 | 4981 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2004 | 521 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1991 | 2866 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2004 | 9198 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 36849 | 0.010 |
Why?
|
| Sarcoma, Experimental | 1 | 1982 | 117 | 0.010 |
Why?
|
| Biotransformation | 1 | 1982 | 166 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 2004 | 574 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2010 | 1893 | 0.010 |
Why?
|
| Clone Cells | 1 | 1985 | 1671 | 0.010 |
Why?
|
| Algorithms | 1 | 2022 | 14154 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 13020 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2006 | 2127 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 7463 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2006 | 977 | 0.010 |
Why?
|
| Lectins | 1 | 1983 | 490 | 0.010 |
Why?
|
| Viral Load | 1 | 2010 | 3398 | 0.010 |
Why?
|
| Hydrogels | 1 | 2006 | 745 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 2002 | 605 | 0.010 |
Why?
|
| Collagen Type I | 1 | 2004 | 620 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 26375 | 0.010 |
Why?
|
| Immunoglobulin E | 1 | 1986 | 1506 | 0.010 |
Why?
|
| Risk Factors | 2 | 2017 | 74962 | 0.010 |
Why?
|
| Peptide Hydrolases | 1 | 1983 | 610 | 0.010 |
Why?
|
| Cell Membrane | 2 | 1982 | 3663 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2021 | 24318 | 0.010 |
Why?
|
| Saquinavir | 1 | 1999 | 29 | 0.010 |
Why?
|
| RNA | 1 | 1989 | 2726 | 0.010 |
Why?
|
| Prevalence | 1 | 1996 | 15872 | 0.010 |
Why?
|
| Indinavir | 1 | 1999 | 73 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2017 | 13052 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1997 | 11918 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2010 | 3048 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2021 | 54920 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 1996 | 15939 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1989 | 4177 | 0.010 |
Why?
|
| Cattle | 1 | 2004 | 3826 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2006 | 2938 | 0.010 |
Why?
|
| Moloney murine leukemia virus | 1 | 1998 | 110 | 0.010 |
Why?
|
| Lac Operon | 1 | 1998 | 237 | 0.010 |
Why?
|
| Community Health Centers | 1 | 2001 | 469 | 0.010 |
Why?
|
| Blood Proteins | 1 | 1983 | 1186 | 0.010 |
Why?
|
| Ritonavir | 1 | 1999 | 330 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2000 | 652 | 0.010 |
Why?
|
| Cytosol | 1 | 2000 | 886 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1998 | 575 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2006 | 2258 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2009 | 6001 | 0.010 |
Why?
|
| Palmitates | 1 | 1976 | 70 | 0.010 |
Why?
|
| Ligands | 1 | 1983 | 3283 | 0.010 |
Why?
|
| Culture Media | 1 | 1998 | 898 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2000 | 739 | 0.010 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1998 | 617 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 2144 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2018 | 42650 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1982 | 1376 | 0.010 |
Why?
|
| HLA-D Antigens | 1 | 1991 | 130 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 1991 | 247 | 0.010 |
Why?
|
| Viral Core Proteins | 1 | 1991 | 158 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1986 | 3777 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1998 | 1943 | 0.010 |
Why?
|
| Child | 1 | 2018 | 80891 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1999 | 6318 | 0.000 |
Why?
|
| Borates | 1 | 1968 | 17 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 1994 | 59686 | 0.000 |
Why?
|
| Injections, Intraperitoneal | 1 | 1968 | 413 | 0.000 |
Why?
|
| Histocytochemistry | 1 | 1968 | 699 | 0.000 |
Why?
|
| p-Methoxy-N-methylphenethylamine | 1 | 1986 | 41 | 0.000 |
Why?
|
| Calcimycin | 1 | 1986 | 214 | 0.000 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2001 | 4047 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1976 | 2421 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1982 | 9261 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 2006 | 15881 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1986 | 2559 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1986 | 2475 | 0.000 |
Why?
|
| Internship and Residency | 1 | 2001 | 5949 | 0.000 |
Why?
|
| Osteoarthritis | 1 | 1986 | 1070 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2001 | 41795 | 0.000 |
Why?
|